Clinical and Experimental Hepatology
eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2025
vol. 11
 
Share:
Send email
Share:
Review paper

Steatotic liver disease and chronic viral hepatitis

Jakub Janczura
1
,
Alessandra Mangia
2
,
Krystyna Dobrowolska
1
,
Michał Brzdęk
1
,
Kinga Brzdęk
1
,
Małgorzata Wajdowicz
3
,
Iwona Gorczyca-Głowacka
4
,
Piotr M. Stępień
5
,
Dorota Zarębska-Michaluk
5

  1. Collegium Medicum, Jan Kochanowski University, Kielce, Poland
  2. Liver Unit, Fondazione “Casa Sollievo della Sofferenza”, IRCCS San Giovanni Rotondo, Rotondo, Italy
  3. Clinical Department of Infectious Diseases with Hepatology Subdivision, Collegium Medicum University of Rzeszow, Rzeszów, Poland
  4. Department of Psychiatry, Jan Kochanowski University, Kielce, Poland
  5. Department of Infectious Diseases and Allergology, Jan Kochanowski University, Kielce, Poland
Clin Exp HEPATOL 2025; 11, 3: 219–227
DOI: https://doi.org/10.5114/ceh.2025.154220
Online publish date: 2025/09/22
Article file
- Steatotic.pdf  [0.21 MB]
Get citation
 
PlumX metrics:
 
1. Teng ML, Ng CH, Huang DQ, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol 2023; 29: S32-S42.
2. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78: 1966-1986.
3. Gorczyca-Głowacka I, Wełnicki M, Mamcarz A, et al. Metabolic associated fatty liver disease and cardiovascular risk: The expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society. Kardiol Pol 2023; 81: 207-214.
4. Amini-Salehi E, Letafatkar N, Norouzi N, et al. Global prevalence of nonalcoholic fatty liver disease: An updated review meta-analysis comprising a population of 78 million from 38 countries. Arch Med Res 2024; 55: 103043.
5. Le MH, Yeo YH, Li X, et al. 2019 global NAFLD prevalence: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2022; 20: 2809-2817.e28.
6. Lee MH, Chen YT, Huang YH, et al. Chronic viral hepatitis B and C outweigh MASLD in the associated risk of cirrhosis and HCC. Clin Gastroenterol Hepatol 2024; 22: 1275-1285.e2.
7. The World Health Organization. Hepatitis C. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.
8. Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018; 69: 896-904.
9. Hui JM, Kench J, Farrell GC, et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002; 17: 873-881.
10. Modaresi Esfeh J, Ansari-Gilani K. Steatosis and hepatitis C. Gastroenterol Rep (Oxf) 2016; 4: 24-29.
11. Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol 2014; 61: S69-78.
12. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-423.
13. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49: 831-844.
14. Hu KQ, Kyulo NL, Esrailian E, et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol 2004; 40: 147-154.
15. Llamosas-Falcón L, Shield KD, Gelovany M, et al. Impact of alcohol on the progression of HCV-related liver disease: A systematic review and meta-analysis. J Hepatol 2021; 75: 536-546.
16. Niezen S, Trivedi HD, Mukamal KJ, Jiang ZG. Associations between alcohol consumption and hepatic steatosis in the USA. Liver Int 2021; 41: 2020-2023.
17. Marti-Aguado D, Calleja JL, Vilar-Gomez E, et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J Hepatol 2024; 81: 930-940.
18. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a metaanalysis of individual patient data. Gastroenterology 2006; 130: 1636-1642.
19. Adinolfi LE, Rinaldi L, Guerrera B, et al. NAFLD and NASH in HCV infection: Prevalence and significance in hepatic and extrahepatic manifestations. Int J Mol Sci 2016; 17: 803.
20. Afsari A, Lee E, Shokrani B, et al. Clinical and pathological risk factors associated with liver fibrosis and steatosis in African Americans with chronic hepatitis C. Dig Dis Sci 2017; 62: 2159-2165.
21. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364.
22. Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol 2021; 27: 1006-1021.
23. Ji D, Chen GF, Niu XX, et al. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. Metabol Open 2021; 10: 100090.
24. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
25. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-641.
26. Restivo L, Zampino R, Guerrera B, et al. Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-alpha-2a plus ribavirin and RVR. J Viral Hepat 2012; 19: 346-352.
27. Aziz H, Gill U, Raza A, Gill ML. Metabolic syndrome is associated with poor treatment response to antiviral therapy in chronic hepatitis C genotype 3 patients. Eur J Gastroenterol Hepatol 2014; 26: 538-543.
28. Brzdęk M, Zarębska-Michaluk D, Invernizzi F, et al. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C. World J Gastroenterol 2023; 29: 949-966.
29. Dobrowolska K, Brzdęk M, Rzymski P, et al. Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals. Expert Opin Pharmacother 2024; 25: 833-852.
30. Flisiak R, Zarębska-Michaluk D, Dobrowolska K, et al. Treatment of HCV infection in patients with steatotic liver disease. Clin Exp Hepatol 2024; 10: 159-164.
31. Rau M, Buggisch P, Mauss S, et al. Prognostic impact of steatosis in the clinical course of chronic HCV infection-Results from the German Hepatitis C-Registry. PLoS One 2022; 17: e0264741.
32. Cespiati A, Coelho Rodrigues I, Santos I, et al. Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: A systematic review. Liver Int. 2024; 44: 1075-1092.
33. Shimizu K, Soroida Y, Sato M, et al. Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter. Sci Rep 2018; 8: 7845.
34. Soliman H, Ziada D, Hamisa M, et al. The effect of HCV eradication after direct-acting antiviral agents on hepatic steatosis: A prospective observational study. Endocr Metab Immune Disord Drug Targets 2022; 22: 100-107.
35. The World Health Organization. Hepatitis C. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
36. Baclig MO, Reyes KG, Liles VR, et al. Hepatic steatosis in chronic hepatitis B: a study of metabolic and genetic factors. Int J Mol Epidemiol Genet 2018; 9: 13-19.
37. Zheng Q, Zou B, Wu Y, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther 2021; 54: 1100-1109.
38. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol 2011; 26: 1361-1367.
39. Yi S, Ren G, Zhu Y, Cong Q. Correlation analysis of hepatic steatosis and hepatitis B virus: a cross-sectional study. Virol J 2024; 21: 22.
40. Hui RWH, Seto WK, Cheung KS, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study. J Viral Hepat 2018; 25: 97-104.
41. Wong SW, Chan WK, Mohamed R. Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B. J Viral Hepat 2020; 27:
42. 1297-1305.
43. Cheng YM, Hsieh TH, Wang CC, Kao JH. Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease. JHEP Rep 2023; 5: 100836.
44. Tang L, Chen C, Gao X, et al. Interleukin 21 reinvigorates the antiviral activity of hepatitis B virus (HBV)-specific CD8+ T cells in chronic HBV infection. J Infect Dis 2019; 219: 750-759.
45. Lv H, Jiang Y, Zhu G, et al. Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection. Sci Rep 2023; 13: 1388.
46. Wu YL, Peng XE, Zhu YB, et al. Hepatitis B virus X .protein induces hepatic steatosis by enhancing the expression of liver fatty acid binding protein. J Virol 2016; 90: 1729-1740.
47. Chan AWH, Wong GLH, Chan HY, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol 2017; 32: 667-676.
48. Lee YB, Ha Y, Chon YE, et al. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. Clin Mol Hepatol 2019; 25: 52-64.
49. Tapper EB, Lok ASF. Use of liver imaging and biopsy in clinical practice. N Engl J Med 2017; 377: 756-768.
50. Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67: 370-398.
51. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67: 1560-1599.
52. Polish Group of Experts for HBV, Flisiak R, Halota W, Jaroszewicz J, et al. Recommendations for the treatment of hepatitis B in 2017. Clin Exp Hepatol 2017; 3: 35-46.
53. Kokkorakis M, Muzurović E, Volčanšek Š, et al. Steatotic liver disease: Pathophysiology and emerging pharmacotherapies. Pharmacol Rev 2024; 76: 454-499.
54. Guirguis E, Dougherty J, Thornby K, et al. Resmetirom: The first Food and Drug Administration–approved medication for nonalcoholic steatohepatitis (NASH). Ann Pharmacother 2025; 59: 162-173.
55. Younossi ZM, Loomba R, Rinella ME, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2018; 68: 361-371.
56. Jiang D, Zhang L, Liu W, et al. Trends in cancer mortality in China from 2004 to 2018: A nationwide longitudinal study. Cancer Commun (Lond) 2021; 41: 1024-1036.
57. Jin X, Chen Y-P, Yang Y, et al. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One 2012; 7: e34198.
58. Janczura J, Brzdęk M, Dobrowolska K, et al. Steatotic liver disease in patients treated for chronic hepatitis B. Pol Arch Intern Med 2025; 135: 16942.
Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.